DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
OLINTATUG TESIRINE
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
OLINTATUG TESIRINE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIPUSTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LIPUSTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AL-901
2
Antibody
Investigational
Unknown
Unknown
Unknown
Ig epsilon chain C region inhibitor
AL-901
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CABOTAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CABOTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AXATILIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasm Metastasis; Neoplasms; Cholangiocarcinoma; Graft vs Host Disease
Macrophage colony stimulating factor receptor inhibitor
AXATILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
R96Z451BMC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANRUKINZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Colitis, Ulcerative
Interleukin-13 inhibitor
ANRUKINZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
OU46IGC49F
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ODRONEXTAMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular
B-lymphocyte antigen CD20 binding agent
ODRONEXTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
8R5CM46UIO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-986253
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BMS-986253
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APLITABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
APLITABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GS-CDA1
2
Antibody
Investigational
Unknown
Unknown
Clostridium Infections
Botulinum neurotoxin type A inhibitor
GS-CDA1
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIBIVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Hepatitis B, Chronic
Unknown
LIBIVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
J1R33H8X7A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
COFETUZUMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
COFETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TIZETATUG REZETECAN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TIZETATUG REZETECAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FONTOLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Interferon gamma inhibitor
FONTOLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
6J92H2439Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SEVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Cytomegalovirus Infections; Cytomegalovirus Retinitis
Envelope glycoprotein H inhibitor
SEVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABITUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Ovarian Neoplasms; Lung Diseases, Interstitial; Prostatic Neoplasms, Castration-Resistant; Scleroderma, Systemic
Integrin alpha-V/beta-1 inhibitor
ABITUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
724QD330RD
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DILPACIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
DILPACIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
F27LAH6D5O
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALEMTUZUMAB BETA
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ALEMTUZUMAB BETA
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOMUZOTUXIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
TOMUZOTUXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5P637IXG16
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMD-273063
2
Antibody
Investigational
Unknown
Unknown
Osteosarcoma; Sarcoma; Melanoma; Neuroblastoma
Disialoganglioside GD2 other
EMD-273063
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ELTREKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ELTREKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REOZALIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
REOZALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SIFALIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Dermatomyositis; Psoriasis; Lupus Erythematosus, Systemic
Interferon alpha inhibitor
SIFALIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
XOY1YA7RMC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-507
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-507
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CUGRASTOMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CUGRASTOMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAPATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Lymphoma, Non-Hodgkin; Multiple Myeloma
TRAIL receptor-1 agonist
MAPATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
WZ1025JPGR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETARACIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Renal Cell; Colorectal Neoplasms; Neoplasms; Arthritis, Rheumatoid; Melanoma; Prostatic Neoplasms, Castration-Resistant; Psoriasis
Integrin alpha-V/beta-3 antagonist
ETARACIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
41W9MFI160
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EURESTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EURESTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CX-072
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
CX-072
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENIBARCIMAB
2
Antibody
Investigational
Unknown
Unknown
Heart Failure; Shock, Septic
ADM stabiliser
ENIBARCIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVDORALIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Pemphigoid, Bullous; Severe Acute Respiratory Syndrome
C5a anaphylatoxin chemotactic receptor inhibitor
AVDORALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
DW4CE8MKS9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BULUMTATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BULUMTATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RILTOVETBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
RILTOVETBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Large B-Cell, Diffuse; Leukemia, Biphenotypic, Acute; Lymphoma, Follicular
CD22 inhibitor
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PUXITATUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PUXITATUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
26
27
28
29
30
31
32
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA